Following the publication and correction of this article [1, 2], an error in Fig 3B(ii) has been identified whereby the wrong panel for ‘Total PARP’ was used inadvertently. The updated figure presents the correct ‘Total PARP’ panel for Fig 3B(ii), and the original, uncropped blots supporting the results in Fig 3B(ii) as well as the individual level data supporting Fig 3A, 3C and 3D have been uploaded as Supporting Information files.
Fig 3. Temporal changes in cell death markers and 18F-ICMT-11 uptake after carboplatin treatment.
A: Time course of changes in caspase 3/7 activity following carboplatin treatment. B: Western blot analysis of the levels of uncleaved PARP, cleaved PARP and cleaved (active) caspase 3 post 50 μM carboplatin treatment (0–96 h) in PC9 (i) and A549 cells (ii). C: Temporal changes in 18F-ICMT-11 uptake in cells following carboplatin treatment. D: Correlation between caspase 3 activity and 18F-ICMT-11 uptake in PC9 cells.
Supporting information
(TIF)
(XLSX)
(XLSX)
(XLSX)
References
- 1.Witney TH, Fortt R, Aboagye EO (2014) Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography. PLoS ONE 9(3): e91694 10.1371/journal.pone.0091694 10.1371/journal.pone.0091694 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.The PLOS ONE Staff (2014) Correction: Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography. PLoS ONE 9(6): e100020 10.1371/journal.pone.0100020 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
(TIF)
(XLSX)
(XLSX)
(XLSX)